The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
A player in the oncology field since 1978, Pierre Fabre has been busy this month advancing its cancer ambitions through a pact with Vernalis (R&D) Ltd. and the acquisition of Vertical Bio.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.
The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.
The bispecific is the first in its class to record a Phase III survival win in small-cell lung cancer, although antibody-drug conjugates and other rivals could challenge in the coming years.
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.
BMS’s Phase III ODYSSEY-HCM study did not show statistical significance for either of its two primary endpoints.
Sanofi’s OX40L candidate missed a Phase II primary endpoint, but the company believes it can still work in a sub-group of ‘heterogeneous inflammatory asthma’ patients.
